...A Soldiers Struggle On and Off The Battlefield As I sit at a stoplight and glare at the pothole I sometimes have to stop, think, and remind myself that it is just a pothole. There is no IED (Improvised Explosive Device) in the pothole. Other times, when I am in Wal-Mart, and the store is very busy I have to calm myself down, and tell myself there is no one here that wants to hurt me. Sometimes the smell of burning plastic or a certain smell which I can't quite put my finger on makes my heart race and puts me back in combat mode. These are just some of the problems soldiers face when they return from war. It is something called PTSD ( Post Traumatic Stress Disorder). In this paper I will discuss the definition of PTSD, soldiers committing crimes, and suicides after deployment. Also, what kinds of treatments that are out there for soldiers. Finally, we will discuss the struggles of a soldier returning home. Post Traumatic Stress Disorder (PTSD) is a condition resulting from exposure to direct or indirect threat of death, serious injury, or a physical threat. Events that can cause PTSD are called "stressors” and may include natural disasters, accidents or deliberate man-made events/disasters, including war. Symptoms of PTSD can include recurrent thoughts of a traumatic event, reduced involvement in work or outside interests, emotional numbing, hyper-alertness, anxiety and irritability. The disorder can be more severe and longer lasting when the stress is human initiated action...
Words: 1599 - Pages: 7
...U.S. Food and Drug Administration (FDA) drug review bears a structural similarity to many decisions made by other regulatory agencies: high uncertainty, low reversibility, avoidance of observable error, and high political stakes that induce lobbying by interested parties. This project explores the policy lessons to be learned from viewing FDA drug review as a politically shaped exercise in information processing. I argue that the incentives facing regulators induce limits on the degree to which drug review can be accelerated, that the same incentives could render privatization initiatives problematic, and that political pressures could play a useful role in identifying priority drugs. Patients, more than pharmaceutical firms, shape the political costs to the FDA of delaying drug approval. Consider two hypothetical consumers, one a pharmaceutical consumer (“patient”) who wishes to try a new drug for some ailment, the other a vitamin consumer who wishes to take zinc supplements to ward off a cold or flu. There are few institutional restrictions upon the consumption decisions of the vitamin consumer, at least in the United States. She is free to purchase vitamin products over the counter, and the vitamin manufacturer is free to sell them without prior authorization or licensing. Not so with pharmaceuticals. The marketplace for pharmaceuticals is one of the most highly regulated industries in the U.S. economy.1 To use any new pharmaceutical product, the patient must secure the...
Words: 5125 - Pages: 21
...Running head: BIPOLAR I & II 1 Bipolar I & II Research Paper (Main Focus on Bipolar II) Perry Blankenship Liberty University BIPOLAR I & II 2 Abstract This paper will cover the diagnoses and treatment of Bipolar II. This paper will show that Bipolar II is found in the Diagnostic and Statistical Manual of Mental Disorders (DSM). This paper will also discuss the use of medication as part of the treatment process for this disorder. This paper will research some of the similar and conflicting attributes of Bipolar I and II. This paper will also show that Bipolar II is a disorder that can be maintained but is never fully cured. This paper will also consider the Christian world view concerning Bipolar Disorder. BIPOLAR I & II 3 According to Maddux and Winstead (2008), Bipolar II is defined as “One or more major depressive episodes accompanied by at least one hypomanic episode.” Bipolar II patients are not as disabled, and they do not present the same psychotic features as Bipolar I patients with manic episodes. When researching information about Bipolar II Disorder a researcher will need to look under...
Words: 4260 - Pages: 18
...General Psychiatry William a. Kehoe, Pharm.D., m.a., FCCP, BCPS University of the Pacific stockton, california © 2009 American College of Clinical Pharmacy 1-281 General Psychiatry Learning Objectives: 1. Describe pharmacotherapeutic options for managing the following psychiatric problems: depression, bipolar disorder, schizophrenia, anxiety disorders, insomnia, and alcohol withdrawal. Describe the drugs used to treat the above disorders in terms of unique pharmacological properties, therapeutic uses, adverse effects, and cognitive and behavioral effects. Formulate a pharmacotherapeutic treatment plan when presented with a patient having depression, bipolar disorder, schizophrenia, an anxiety disorder, or insomnia. Discuss the treatment of substance abuse using alcohol abuse as a model. 4. 2. C. Theophylline. D. Pseudoephedrine. Which one of the following antidepressants would be least likely to cause drug-disease or drug-drug interactions for T.N.? A. Venlafaxine. B. Fluvoxamine. C. Phenelzine. D. Fluoxetine. Which one of the following periods represents the continuation therapy phase for T.N.’s depression? A. 6–12 weeks. B. 12–16 weeks. C. 6–12 months. D. 2−3 years. T.N. will be seen initially at monthly intervals to assess antidepressant therapy. Which one of the following instruments is a patient-completed measure of depressive symptoms that could be used to assess his response? A. Hamilton Rating Scale for Depression. B. Montgomery-Åsberg Depression Rating Scale...
Words: 21139 - Pages: 85
